EG24412A - Novel compounds - Google Patents

Novel compounds

Info

Publication number
EG24412A
EG24412A EG86498A EG86498A EG24412A EG 24412 A EG24412 A EG 24412A EG 86498 A EG86498 A EG 86498A EG 86498 A EG86498 A EG 86498A EG 24412 A EG24412 A EG 24412A
Authority
EG
Egypt
Prior art keywords
novel compounds
novel
compounds
Prior art date
Application number
EG86498A
Other languages
English (en)
Inventor
Simon Guile
Anthony Ingall
Brian Springthorpe
Paul Willis
Original Assignee
Astra Pharma Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26663042&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EG24412(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE9702775A external-priority patent/SE9702775D0/xx
Priority claimed from SE9702773A external-priority patent/SE9702773D0/xx
Application filed by Astra Pharma Prod filed Critical Astra Pharma Prod
Application granted granted Critical
Publication of EG24412A publication Critical patent/EG24412A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
EG86498A 1997-07-22 1998-07-22 Novel compounds EG24412A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9702775A SE9702775D0 (sv) 1997-07-22 1997-07-22 Novel compounds
SE9702773A SE9702773D0 (sv) 1997-07-22 1997-07-22 Novel compounds

Publications (1)

Publication Number Publication Date
EG24412A true EG24412A (en) 2009-05-25

Family

ID=26663042

Family Applications (1)

Application Number Title Priority Date Filing Date
EG86498A EG24412A (en) 1997-07-22 1998-07-22 Novel compounds

Country Status (31)

Country Link
EP (1) EP0996621B1 (fr)
JP (1) JP4187406B2 (fr)
KR (2) KR20050084540A (fr)
CN (1) CN1154650C (fr)
AR (2) AR017014A1 (fr)
AT (1) ATE251161T1 (fr)
AU (1) AU745381B2 (fr)
BR (1) BR9810802B1 (fr)
CA (1) CA2296665C (fr)
CZ (1) CZ302629B6 (fr)
DE (1) DE69818668T2 (fr)
DK (1) DK0996621T3 (fr)
EE (1) EE04193B1 (fr)
EG (1) EG24412A (fr)
ES (1) ES2207846T3 (fr)
HK (1) HK1026421A1 (fr)
HU (1) HU230074B1 (fr)
IL (2) IL133959A0 (fr)
IS (1) IS2236B (fr)
MY (1) MY123196A (fr)
NO (1) NO315854B1 (fr)
NZ (1) NZ502381A (fr)
PL (1) PL200325B1 (fr)
PT (1) PT996621E (fr)
RU (1) RU2225407C2 (fr)
SA (1) SA98190487B1 (fr)
SK (1) SK284199B6 (fr)
TR (1) TR200000197T2 (fr)
TW (1) TW530058B (fr)
UA (1) UA66801C2 (fr)
WO (1) WO1999005143A1 (fr)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229674B (en) * 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
SE9903290D0 (sv) * 1999-09-15 1999-09-15 Astra Pharma Prod Novel compounds
SE9904129D0 (sv) * 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
SE9904128D0 (sv) * 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
GB0013487D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Novel process
GB0013488D0 (en) 2000-06-02 2000-07-26 Astrazeneca Ab Chemical compound
AR028110A1 (es) * 2000-06-02 2003-04-23 Astrazeneca Ab Nuevo proceso
GB0013407D0 (en) 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
IT1317049B1 (it) * 2000-06-23 2003-05-26 Sigma Tau Ind Farmaceuti Composti utili per la preparazione di medicamenti ad attivita'inibitrice della fosfodiesterasi iv.
SE0004098D0 (sv) 2000-11-09 2000-11-09 Astrazeneca Ab Novel compounds
SE0004099D0 (sv) * 2000-11-09 2000-11-09 Astrazeneca Ab Novel compounds
GB0219746D0 (en) * 2002-08-23 2002-10-02 Inst Of Ex Botany Ascr Azapurine derivatives
DE602004027409D1 (de) 2003-10-21 2010-07-08 Inspire Pharmaceuticals Inc Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation
US7504497B2 (en) 2003-10-21 2009-03-17 Inspire Pharmaceuticals, Inc. Orally bioavailable compounds and methods for inhibiting platelet aggregation
US7335648B2 (en) 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
US7749981B2 (en) 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
SE0401001D0 (sv) 2004-03-31 2004-03-31 Astrazeneca Ab Chemical process
US7932376B2 (en) 2005-05-05 2011-04-26 Inspire Pharmaceuticals, Inc. Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation
GB0615620D0 (en) 2006-08-05 2006-09-13 Astrazeneca Ab A process for the preparation of optically active intermediates
CA2668180A1 (fr) 2006-10-31 2008-05-08 Janssen Pharmaceutica N.V. Derives de triazolopyrimidine convenant comme antagonistes du recepteur p2y12 de l'adp
UA100864C2 (uk) * 2007-12-03 2013-02-11 Астразенека Аб Спосіб лікування або запобігання аневризмі черевної аорти
SG196805A1 (en) 2008-09-09 2014-02-13 Astrazeneca Ab A process for preparing [1s- [1-alpha, 2-alpha, 3-beta (1s*, 2r*) 5-beta] ] -3- [7- [2- (3, 4-dif luorophenyl) -cyclopropylamino] - 5- (propylthio) -3h-1, 2, 3-triazolo [4, 5-d] pyrimidin-3-yl] -5- (2- hydroxyethoxy) cyclopentane-1, 2-diol and to its intermediates
WO2010043721A1 (fr) 2008-10-17 2010-04-22 Oryzon Genomics, S.A. Inhibiteurs d’oxydases et leur utilisation
EP2389362B1 (fr) 2009-01-21 2019-12-11 Oryzon Genomics, S.A. Dérivés de phénylcyclopropylamine et leur utilisation médicale
US8389580B2 (en) 2009-06-02 2013-03-05 Duke University Arylcyclopropylamines and methods of use
EP2305376A1 (fr) 2009-09-23 2011-04-06 Lonza Ltd. Procédé et catalyseur pour l'hydrogénation catalytique de composés de nitro aromatiques et hétéro-aromatiques
CN102639496B (zh) 2009-09-25 2014-10-29 奥瑞泽恩基因组学股份有限公司 赖氨酸特异性脱甲基酶-1抑制剂及其应用
EP2486002B1 (fr) 2009-10-09 2019-03-27 Oryzon Genomics, S.A. Acétamides d'hétéroaryl- et aryl-cyclopropylamine substitués et leur utilisation
WO2011067571A1 (fr) 2009-12-03 2011-06-09 Astrazeneca Ab Co-cristaux d'un inhibiteur d'agrégation plaquettaire à base de triazolo [4,5-d] pyrimidine
CA2785487C (fr) 2009-12-23 2017-11-28 Ratiopharm Gmbh Forme solide de dosage pharmaceutique
US8859769B2 (en) 2010-02-16 2014-10-14 Actavis Group Ptc Ehf Processes for preparing ticagrelor intermediate, 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine
US9616058B2 (en) 2010-02-24 2017-04-11 Oryzon Genomics, S.A. Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use
WO2011106573A2 (fr) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibiteurs de la lysine déméthylase utilisés dans le traitement et la prévention de maladies et de troubles associés à hepadnaviridae
BR112012026694A2 (pt) 2010-04-19 2016-07-12 Oryzon Genomics Sa inibidores da desmetilase específica para lisina 1 e seu uso
CA2796504A1 (fr) 2010-04-20 2011-10-27 Actavis Group Ptc Ehf Nouveau procede de preparation de derives de phenylcyclopropylamine par utilisation de nouveaux intermediaires
EP2588441A2 (fr) 2010-06-30 2013-05-08 Actavis Group Ptc Ehf Nouveaux procédés pour la préparation de dérivés de phénylcyclopropylamine et leur utilisation pour la préparation de ticagrelor
WO2012013727A1 (fr) * 2010-07-29 2012-02-02 Oryzon Genomics S.A. Dérivés de cyclopropylamine utiles en tant qu'inhibiteurs de lsd1
WO2012013728A1 (fr) 2010-07-29 2012-02-02 Oryzon Genomics S.A. Inhibiteurs de déméthylase lsd1 base d'aryclcyclopropylamine et leur utilisation médicale
US9061966B2 (en) 2010-10-08 2015-06-23 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012063126A2 (fr) 2010-11-09 2012-05-18 Actavis Group Ptc Ehf Procédés améliorés de préparation de (3ar,4s,6r,6as)-6-amino-2,2-diméthyltétrahdro-3ah-cyclopenta[d] [1,3]-dioxol-4-ol pur et son matériau de départ clé
WO2012072713A2 (fr) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Inhibiteurs de la déméthylase spécifique de la lysine pour des maladies et troubles liés aux flaviviridés
CN103429576A (zh) 2010-12-20 2013-12-04 阿特维斯集团公司 制备三唑并[4,5-d]嘧啶衍生物及其中间体的新方法
WO2012107498A1 (fr) 2011-02-08 2012-08-16 Oryzon Genomics S.A. Inhibiteurs de lysine diméthylase pour des troubles myéloprolifératifs
CN102731510B (zh) * 2011-04-07 2015-12-16 博瑞生物医药（苏州）股份有限公司 替卡格雷的衍生物、制备方法及其药物用途
CN103764149A (zh) 2011-06-01 2014-04-30 阿斯利康(瑞典)有限公司 新型替卡格雷共晶
EP2721018A1 (fr) 2011-06-15 2014-04-23 Actavis Group Ptc Ehf Procédé amélioré de préparation de dérivés de cyclopentanamine et de leurs intermédiaires
CN102924457A (zh) * 2011-08-12 2013-02-13 上海恒瑞医药有限公司 三唑并嘧啶类衍生物、其制备方法及其用途
RU2681211C2 (ru) 2011-10-20 2019-03-05 Оризон Дженомикс С.А. (гетеро)арилциклопропиламины в качестве ингибиторов lsd1
SG11201401066PA (en) 2011-10-20 2014-10-30 Oryzon Genomics Sa (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
PL2771326T4 (pl) * 2011-10-27 2018-06-29 Lek Pharmaceuticals D.D. Synteza związków triazolopirymidynowych
EP2589587A1 (fr) 2011-11-04 2013-05-08 Chemo Ibérica, S.A. Synthèse de cyclopropanes à substitution azote
AU2012343928A1 (en) 2011-11-30 2014-05-29 Actavis Group Ptc Ehf Novel crystalline form of ticagrelor and process for the preparation thereof
US20130178520A1 (en) 2011-12-23 2013-07-11 Duke University Methods of treatment using arylcyclopropylamine compounds
EP2834247A4 (fr) 2012-04-05 2016-03-30 Reddys Lab Ltd Dr Préparation de ticagrelor
CN102675321B (zh) * 2012-05-11 2014-12-10 上海皓元化学科技有限公司 一种替卡格雷的制备方法
CN103626743B (zh) * 2012-08-23 2018-06-08 广东东阳光药业有限公司 替卡格雷的新型中间体及其制备方法
CZ2012705A3 (cs) 2012-10-16 2014-04-23 Zentiva, K.S. Pevná orální farmaceutická formulace obsahující ticagrelor
WO2014083139A1 (fr) 2012-11-29 2014-06-05 Actavis Group Ptc Ehf Nouvelle forme amorphe de ticagrelor
CN103965198A (zh) * 2013-02-05 2014-08-06 郝聪梅 替卡格雷的中间体及其制备方法以及利用该中间体制备替卡格雷的方法
CN103183679A (zh) * 2013-03-20 2013-07-03 西藏海思科药业集团股份有限公司 抗凝血化合物及其应用
CN104098553B (zh) * 2013-04-10 2017-11-28 江苏恒瑞医药股份有限公司 替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法
CA2913326A1 (fr) 2013-05-29 2014-12-04 Ratiopharm Gmbh Forme posologique pharmaceutique solide
WO2014206187A1 (fr) * 2013-06-24 2014-12-31 苏州明锐医药科技有限公司 Procédé de préparation du ticagrelor et de ses intermédiaires
CN103588751B (zh) * 2013-11-07 2014-12-17 苏州明锐医药科技有限公司 替格瑞洛中间体的制备方法
WO2015162630A1 (fr) 2014-04-25 2015-10-29 Anlon Chemical Research Organization Nouveaux procédés de préparation de triazolo[4,5-d]-pyrimidines, dont le ticagrelor, via de nouveaux intermédiaires et une nouvelle voie de synthèse
WO2015193165A1 (fr) 2014-06-18 2015-12-23 Flamma Spa Procédé pour la préparation de composés de triazolo[4,5-d]pyrimidine cyclopentane
CN105272985B (zh) * 2014-06-24 2017-11-21 珠海联邦制药股份有限公司 三唑并[4,5‑d]嘧啶化合物及其合成方法、用途、组合物
AU2015326869B2 (en) 2014-10-01 2021-04-29 Medimmune Limited Antibodies to ticagrelor and methods of use
WO2016116942A1 (fr) 2015-01-20 2016-07-28 Anlon Chemical Research Organization Nouveaux composés pharmaceutiques comprenant du ticagrélor avec des sels d'aspirine
CN105985346B (zh) * 2015-03-06 2019-10-18 苏州朗科生物技术股份有限公司 一种新的替格瑞洛化合物制备方法及其中间体化合物
TR201601835A2 (tr) 2016-02-12 2017-08-21 Ali Raif Ilac Sanayi Ve Ticaret Anonim Sirketi Ti̇kagrelor i̇çeren formülasyonlar i̇çi̇n üreti̇m yöntemi̇
SG11201808220VA (en) 2016-03-22 2018-10-30 Merck Sharp & Dohme Allosteric modulators of nicotinic acetylcholine receptors
WO2018167447A1 (fr) 2017-03-14 2018-09-20 University Of Sheffield Aspirine à faible dose (1-50 mg) conjointement avec des antiagrégants plaquettaires de type ticagrelor d'anticoagulants
CN107141298A (zh) * 2017-07-24 2017-09-08 苏州信恩医药科技有限公司 一种替格瑞洛的合成方法
TWI641327B (zh) * 2017-09-30 2018-11-21 双邦實業股份有限公司 Socks that are comfortable and comfortable to wear
EP3527571A1 (fr) * 2018-02-14 2019-08-21 Université de Liège Dérivés de pyrimidine pour la prévention et le traitement d'infections bactériennes
WO2023213198A1 (fr) * 2022-05-04 2023-11-09 华东师范大学 Utilisation d'un composé cyclique fusionné aromatique en tant qu'activateur de trek-1 et composition pharmaceutique et analgésique le contenant
CN114805367B (zh) * 2022-05-24 2023-04-07 郑州大学 一种三氮唑并嘧啶类衍生物及其制备方法和应用
CN115710275B (zh) * 2022-11-21 2024-02-02 河南中医药大学 一种嘧啶-tcp类化合物、制备方法和医药用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4742064A (en) * 1985-09-10 1988-05-03 Regents Of The University Of Minnesota Antiviral carbocyclic analogs of xylofuranosylpurines
GB8826205D0 (en) * 1988-11-09 1988-12-14 Wellcome Found Heterocyclic compounds
DE3924424A1 (de) * 1989-07-24 1991-01-31 Boehringer Mannheim Gmbh Nucleosid-derivate, verfahren zu deren herstellung, deren verwendung als arzneimittel sowie deren verwendung bei der nucleinsaeure-sequenzierung
IL122814A (en) * 1995-07-11 2001-04-30 Astrazeneca Ab Acid 1 - [1, 2, 3, - Triazolo [4, 5, - [d pyrimidine - 3 - il] Ribo - the photopornorone, converted in positions 5 and 7 and its analogues, their preparation and pharmaceutical preparations containing them
AU5501598A (en) * 1996-12-20 1998-07-17 Astra Pharmaceuticals Limited Triazolo{4,5-(d)}pyrimidinyl derivatives and their use as medicaments

Also Published As

Publication number Publication date
TR200000197T2 (tr) 2000-06-21
EE200000044A (et) 2000-10-16
BR9810802B1 (pt) 2010-10-19
JP4187406B2 (ja) 2008-11-26
RU2225407C2 (ru) 2004-03-10
HU230074B1 (hu) 2015-06-29
IS2236B (is) 2007-05-15
SK188199A3 (en) 2000-10-09
CZ302629B6 (cs) 2011-08-10
CZ2000233A3 (cs) 2000-07-12
KR20010022083A (ko) 2001-03-15
AR017014A1 (es) 2001-08-22
UA66801C2 (uk) 2004-06-15
JP2001510842A (ja) 2001-08-07
HUP0004333A3 (en) 2001-11-28
EP0996621B1 (fr) 2003-10-01
SK284199B6 (sk) 2004-10-05
TW530058B (en) 2003-05-01
CA2296665A1 (fr) 1999-02-04
PL200325B1 (pl) 2008-12-31
IL133959A (en) 2007-10-31
AU745381B2 (en) 2002-03-21
PT996621E (pt) 2004-02-27
CA2296665C (fr) 2008-06-10
NO315854B1 (no) 2003-11-03
AU8370698A (en) 1999-02-16
CN1270590A (zh) 2000-10-18
PL338516A1 (en) 2000-11-06
CN1154650C (zh) 2004-06-23
EP0996621A1 (fr) 2000-05-03
AR077553A2 (es) 2011-09-07
BR9810802A (pt) 2000-09-12
DE69818668T2 (de) 2004-08-12
KR20050084540A (ko) 2005-08-26
IL133959A0 (en) 2001-04-30
EE04193B1 (et) 2003-12-15
DK0996621T3 (da) 2004-02-02
SA98190487B1 (ar) 2006-08-20
NZ502381A (en) 2001-12-21
HUP0004333A2 (hu) 2001-04-28
MY123196A (en) 2006-05-31
IS5354A (is) 2000-01-20
DE69818668D1 (de) 2003-11-06
ATE251161T1 (de) 2003-10-15
NO20000312L (no) 2000-03-21
WO1999005143A1 (fr) 1999-02-04
KR100535837B1 (ko) 2006-01-12
NO20000312D0 (no) 2000-01-21
HK1026421A1 (en) 2000-12-15
ES2207846T3 (es) 2004-06-01

Similar Documents

Publication Publication Date Title
EG24412A (en) Novel compounds
EG24177A (en) Novel compounds
GB9706255D0 (en) Novel compounds
GB9707830D0 (en) Novel compounds
GB9703492D0 (en) Novel compounds
GB9709521D0 (en) Novel compounds
GB9709094D0 (en) Novel compounds
GB9708174D0 (en) Novel compounds
GB9708095D0 (en) Novel compounds
GB9700591D0 (en) Novel compounds
GB9700687D0 (en) Novel compounds
GB9705385D0 (en) Novel compounds
GB9705619D0 (en) Novel compounds
GB9705620D0 (en) Novel compounds
GB9704461D0 (en) Novel compounds
GB9706525D0 (en) Novel compounds
GB9700688D0 (en) Novel compounds
GB9703491D0 (en) Novel compounds
GB9703402D0 (en) Novel compounds
GB9703334D0 (en) Novel compounds
GB9700281D0 (en) Novel compounds
GB9706827D0 (en) Novel compounds
GB9713011D0 (en) Novel compounds
GB9703011D0 (en) Novel compounds
GB9709520D0 (en) Novel compounds